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The idiopathic inflammatory myopathies (IIMs), also known as myositis, are a diverse group of auto immune diseases that are characterized by chronic muscle inflammation and associated muscle weak ness. However, the IIMs are complex, systemic diseases with skeletal muscle involvement and frequent mani festations in other organ systems, including the skin, joints and cardiopulmonary, gastrointestinal and con stitutional systems. The most common forms of IIM are dermatomyositis, polymyositis and inclusion body myositis (IBM) in adults and dermatomyositis in chil dren (juvenile dermatomyositis). To adequately evaluate patients, assess their responses to therapies and track longterm outcomes, IIM researchers must assess the following constructs: disease activity, that is, the type, extent and severity of reversible pathological manifes tations of IIM; disease damage, which includes persis tent changes from previously active disease (related to scarring, atrophy or fibrosis), longterm complications of therapy or comorbid conditions; patient-reported outcome measures (PROMs), including patient reports about physical function and health-related quality of life (HRQoL); and objective measures, such as imaging and biomarkers 1 . International collaborative groups comprising clinicians and researchers with a special interest in IIM, which include the International Myositis Assessment and Clinical Studies Group (IMACS) and the Paediatric Rheumatology International Trials Organisation (PRINTO) 2 , have developed standardized, wellvalidated assessment measures to evaluate these constructs. In this Review, we discuss developments in the past few years in the assessment of IIM outcomes and summarize the major tools available to clinicians and researchers to evaluate the outcome of IIM treatment.
Core set measures
Core set measures (CSMs) are the minimum set of meas ures that are required to comprehensively assess disease and that should be carried out and reported in all clinical studies and therapeutic trials. International consortia of collaborating IIM investigators have developed and val idated CSMs (TABLE 1) to assess disease activity in adult patients with dermatomyositis or polymyositis (IMACS) and in children with juvenile dermatomyositis (IMACS and PRINTO) 3 . These measures are practical, well stand ardized and reliable; they are easy to use in multicentre international studies, they are applicable to all forms of IIMs, and they are well validated. The PRINTO CSMs Patient-reported outcome measures (PROMs) . Measurements based on information provided directly by the patient (that is, the study subject) about the status of his or her health condition, without amendment or interpretation of the patient's response by a clinician or anyone else.
Health-related quality of life (HRQoL) . A multidimensional assessment of a subject's health that includes domains related to physical, mental, emotional and social functioning. HRQoL goes beyond direct measures of health, life expectancy and causes of death and focuses on the effect that health status has on quality of life. 4 , Ann M. Reed 5 , Lisa Christopher-Stine 6 and Nicolino Ruperto 7 Abstract | The adult and juvenile myositis syndromes, commonly referred to collectively as idiopathic inflammatory myopathies (IIMs), are systemic autoimmune diseases with the hallmarks of muscle weakness and inflammation. Validated, well-standardized measures to assess disease activity, known as core set measures, were developed by international networks of myositis researchers for use in clinical trials. Composite response criteria using weighted changes in the core set measures of disease activity were developed and validated for adult and juvenile patients with dermatomyositis and adult patients with polymyositis, with different thresholds for minimal, moderate and major improvement in adults and juveniles. Additional measures of muscle strength and function are being validated to improve content validity and sensitivity to change. A health-related quality of life measure, which incorporates patient input, is being developed for adult patients with IIM. Disease state criteria, including criteria for inactive disease and remission, are being used as secondary end points in clinical trials. MRI of muscle and immunological biomarkers are promising approaches to discriminate between disease activity and damage and might provide much-needed objective outcome measures. These advances in the assessment of outcomes for myositis treatment, along with collaborations between international networks, should facilitate further development of new therapies for patients with IIM.
Biomarkers
Measurable indicators of normal biological processes, pathogenic processes or responses to an exposure or intervention, including therapeutic interventions.
Core set measures (CSMs) . The minimum set of validated assessments that are recommended to be used in therapeutic trials and natural history studies.
Response criteria
A set of conditions, usually involving combinations of assessment tools, that define clinically important improvement in disease symptoms and signs. These criteria allow investigators, clinicians, regulators and patients to determine the efficacy (or lack thereof) of a therapeutic intervention, and they facilitate communication between these parties about response to treatment by using the same metric.
of disease activity for juvenile dermatomyositis received provisional acceptance by both the ACR and EULAR 3, 4 . The IMACS CSMs have been recommended for use in patients with IBM, although supporting validation stud ies are lacking, and therefore they are not universally accepted for this subgroup 5 . The CSMs of disease activity are also responsive to changes in disease activity, as demonstrated in sev eral therapeutic trials in children with juvenile der matomyositis and in adults with dermatomyositis or poly myositis [6] [7] [8] [9] [10] . The minimal clinically meaningful change in each disease activity measure has also been established as ≥20% improvement for all IMACS or PRINTO CSMs, except for ≥30% improvement in mus cle enzymes; moderate and major changes in CSMs of activity have also been defined 11 . The relative importance of each measure in assessing changes in disease activity has been determined using conjoint analysis, which iden tified muscle strength as the most important measure, followed by physician global activity (PGA) and extra muscular activity for adult and juvenile patients with dermatomyositis and adult patients with polymyositis 11 . One of the primary CSMs for disease damage, the Myositis Damage Index, has been validated for adult dermatomyositis and polymyositis and for juvenile der matomyositis and was used in several studies to assess longterm outcomes and disease sequelae (reviewed elsewhere 3 ). Other measures of disease damage include physician global damage (on a 10 cm Likert scale), as well as measures of physical function (TABLE 1) . In addition, a measure of strength, as well as the effects of disease damage on growth and development, is also recom mended by the PRINTO for the assessment of damage in patients with juvenile dermatomyositis 4 . The CSMs of disease activity and damage have been widely adopted not only by the IMACS and the PRINTO but also by other groups 12, 13 . Limitations of the CSMs include a lack of validation in patients with IBM and variations between specialists in assessments of strength and function, as discussed below.
IIM response criteria
Response criteria provide standardized measurements of changes in disease activity in response to a therapeutic intervention and of the therapeutic efficacy of a treat ment 14 . The initial partially validated response criteria that were established for juvenile dermatomyositis and adult dermatomyositis or polymyositis included the pre liminary definitions of improvement, which required ≥20% improvement in a minimum of three of six CSMs of disease activity to establish that patients showed a minimal clinically meaningful improvement 15, 16 . These preliminary response criteria were used successfully as primary end points in several therapeutic trials, but they define only the minimal clinical improvement, they were only partially validated, and they lacked sufficient sensitivity and discriminatory validity in randomized trials [6] [7] [8] [9] [10] . The development of datadriven and consensus driven conjoint analysisbased hybrid response criteria for adult patients with dermatomyositis or poly myositis and children with juvenile dermatomyositis, including quantitative assessment of improvement on a contin uous scale and different thresholds for minimal, mod erate and major improvement, marks a major advance in assessing the response to treatment in clinical trials and studies of patients with IIMs 11 . These composite response criteria are based on weighted scores that are applied to absolute percentage improvement in the six CSMs (TABLE 2) . The criteria were developed using data sets with many patients, novel conjoint analysis method ology [17] [18] [19] [20] [21] , clinical trial validation and consensus among experts in adult and paediatric myositis who specialize in rheumatology, neurology or dermatology. These criteria are now approved as the final IIM response criteria by the ACR and the EULAR [22] [23] [24] [25] and are the same for adult and juvenile patients, although the criteria have different thresholds to reflect the difference in responses between adults and children.
The 2016 ACR-EULAR IIM response criteria for adult patients with polymyositis or dermatomyositis and children with juvenile dermatomyositis are hybrid criteria [22] [23] [24] [25] , that is, the same criteria can be used either as a continuous outcome or as a categorical outcome. These criteria generate a total improvement score (TIS; on a scale of 0-100) that provides a quantitative measure of improvement for each subject, which can be compared between treatment arms using the mean or median scores of all enrolled patients. The TIS is the sum of the improvement in each of the six CSMs of disease activity, but the individual CSMs are weighted, such that CSMs that are considered more important contribute more to
• The primary assessment of myositis includes core set measures of disease activity and disease damage and measures of patient-reported outcomes.
• A new composite myositis response criterion, which combines and differentially weights core set activity measures to determine minimal, moderate and major clinical response, has been developed and validated.
• Measures of muscle strength and function are being refined for myositis subgroups and are being used as primary or secondary outcome measures in studies and clinical trials in patients with myositis.
• Disease-specific patient-reported outcomes, including health-related quality of life measures that reflect patient perspectives, are being developed.
• Imaging and immunological biomarkers provide objective measures that can discriminate disease activity from disease damage, but they still require validation in clinical trials.
Manual muscle testing (MMT). A method for assessing the strength of individual muscle groups on the basis of performing a movement in relation to the forces of gravity and manual resistance by the examiner.
the final score. For example, changes in the manual muscle testing (MMT) and PGA scores are weighted more heav ily than changes in the Health Assessment Questionnaire (HAQ) or in the enzyme with the most abnormal activity in serum. Continuous measures might allow for better statistical power (which is especially useful for pilot studies) and have greater sensitivity to change 26 . The criteria also provide categorical outcomes of min imal, moderate and major improvement, allowing the proportion of patients who show a desired response to be compared between treatment arms. However, these new response criteria also have several limitations; most nota bly, they cannot be used for disease flare or remission states
.
Muscle strength and function measures
Muscle weakness is the primary feature of the IIMs and varies in location, severity and progression according to the phenotype and the patient [27] [28] [29] [30] [31] . Muscle weakness results in functional limitations (disability) that can be assessed by standardized motor tasks or estimated by questionnaires and scales. Although measures of muscle strength and function are part of the CSMs, additional measures of strength and function have been examined to improve performance and measurement sensitivity, cover aspects of disease that are not adequately assessed by CSMs and develop more appropriate measures that are applicable to patients with IBM. The assessment of muscle strength and function requires adequate assessor b The muscle enzyme that has the most abnormal serum activity (among creatine kinase, aldolase, alanine aminotransferase, aspartate aminotransferase and lactate dehydrogenase).
c The total improvement score is the sum of all six improvement scores associated with the change in each core set measure. Adapted with permission from REF. 22 
Dynamometers
Devices that measure muscle strength during muscle contraction, such as gripping, pushing and pulling.
training and patient participation to ensure optimal per formance. The choice of assessment tool should be based on the study population and on the goals of the study or clinical trial.
Muscle strength assessment measures. Muscle strength can be measured by several techniques (TABLE 3) , usually in isometric conditions. MMT is the most commonly used technique in the clinic, has been validated for dermatomyositis, polymyositis and juvenile dermato myositis 3, 27 , is a CSM 1, 4 and has been used as a primary or secondary outcome measure in many therapeutic trials in patients with IIM 1, [6] [7] [8] [9] [10] [11] . MMT has high practical ity and low time and equipment requirements, as well as adequate interrater and intrarater reliability and validity when MMT is carried out by a trained exam iner 32 . The limitations of MMT include poor sensitivity to change as well as floor and ceiling effects in natural history studies 3, 27, 33 , although MMT has demonstrated good sensitivity to change in some clinical trials and has also performed well in natural history studies 1, [6] [7] [8] 10 . Furthermore, muscle strength assessed by MMT seems to improve less than other CSMs in patients who are improving 11 . However, in two small therapeutic tri als of patients with dermatomyositis or polymyositis, MMT and fixed dynamometry (measured by maximal voluntary isometric contraction testing) had a similar responsiveness to change 8, 34 . Another advantage of MMT is that scores from different muscle groups can be aggre gated to generate composite scores that can be used to gauge overall improvement or progression in both clin ical practice and therapeutic trials, which is not possi ble using absolute values of strength that are measured using dynamometers.
Muscle strength is increasingly being evaluated using dynamometerbased methods, which are used primar ily in patients with IBM and other neuromuscular dis eases and are rarely used in patients with polymyositis or dermatomyositis 28, 29 . The clinometric properties of the measures depend on the metrological features of the dynamometer and on the operating procedures that are utilized. One of the advantages of dynamometry is that it is more objective and less examiner dependent than MMT. Combining the strength of different muscle groups is not consistent, however, owing to the diver sity in their ranges. To calculate composite values, it is necessary to express the primary data as a percentage of predicted values on the basis of patients' age, weight, height and/or sex (that is, normative data). Normative data exist for most of the muscle strength assessment methods and for all age groups, including children, adolescents and adults (TABLE 3) . Depending on the tech nique, dynamometry might also have floor and ceiling effects, although to a lesser extent than MMT 29 . In IBM trials, handheld dynamometry and maximal voluntary isometric contraction testing (mostly using handheld International Trials Organisation (PRINTO) CSMs can be used to define improvement with the juvenile dermatomyositis response criteria
Disadvantages
• Some of the CSMs that the criteria are based on are subjective and evaluator dependent • Validation of the final criteria and thresholds for improvement was based on limited data • The threshold for a major response for adult dermatomyositis and polymyositis is preliminary: further data are needed to confirm the threshold • The criteria fail to differentiate between no change and a worsening of disease • The criteria cannot be used for disease flare or relapse • The criteria do not define remission • The criteria were developed for major clinical phenotypes (dermatomyositis, polymyositis and juvenile dermatomyositis); although there is no validation for other phenotypes (immune-mediated necrotizing myopathy or antisynthetase syndrome), the criteria are likely to work for these phenotypes as well • The criteria are difficult to use in everyday clinical practice without the use of a computer The Table S1 ). The generation of strength leads to the gen eration of movements that are organized to accomplish adultrelated or childrelated motor tasks. The ability to complete motor tasks can be evaluated by the time required to perform them (using timed tests) or the way that they are performed and/or the difficulty in performing them (using scales and questionnaires). The Childhood Myositis Assessment Scale (CMAS), which assesses muscle strength, observed function and endurance, is the bestvalidated observational functional test and has also been used in therapeutic trials and is a CSM for juvenile dermatomyositis 3, 4, 7 .The Functional Index2 (FI2) is an observational measure of muscle fatigue in which patients perform repetitive movements in 11 proximal and distal muscle groups of the upper and lower extremities, and it has good construct and con tent validity and good rater reliability in adult patients with dermatomyositis or polymyositis 3, 36 . The FI2 is being used as a secondary end point in therapeutic tri als in dermatomyositis and polymyositis 9, 10 . The FI2 is well tolerated by patients and does not require expen sive equipment, and a unilateral FI2 test requires only 20 minutes to complete. A new hybrid measure of mus cle strength and function -a composite of the MMT on a subset of eight muscles (MMT8) and three items of the CMAS -was developed for patients with juvenile dermatomyositis and was validated in studies of three large multinational cohorts 37 . In neuromuscular disorders, several timed tests to assess muscle function, endurance and fatigability have been used in therapeutic trials or observational studies. In addition to the FI2 (REFS 3,38), these tests include the 2minute or 6minute walking distance test (2MWDT or 6MWDT) 39 , the timed 10 m walk or run test 40 , the timed upandgo (TUG) test 39, 41, 42 , the 30second chair stand test (30sCST) 43, 44 and the Short Physical Performance Battery 45, 46 (TABLE 4) . Except for the 6MWDT, these tests have not been validated in adult or juvenile patients with IIM. The 6MWDT has been widely used to assess gait performance and endurance capacity and was in 2016 used as the primary end point in the bimagrumab therapeutic trial in patients with IBM, the largest IBM trial to date 47 . In patients with IBM, a moderate cor relation between the 2MWDT and the 6MWDT was shown, although the 2MWDT was more feasible and less onerous for patients 48 . To avoid patient fatigue, the number of observational functional tests must be lim ited. The tests must be selected based on the patient's characteristics and must be highly standardized. Normative data exist for most of the functional tests, and results can be expressed as a percentage of predicted normal values. Validated functional measures can be a strong secondary end point in clinical trials or studies of patients with IIM, especially in patients who have baseline muscle weakness.
By contrast, questionnaires and scales that evaluate a patient's or parent's selfreport of performance of com mon functions of daily activities can be selfadministered or administered by an interviewer. Although functional questionnaires have the substantial advantages of fea sibility and ease of administration, they have the limi tation of not directly assessing physical activity. These questionnaires are discussed below (Supplementary  Table S1 ).
Physical activity monitoring.
Habitual physical activ ity can also be measured at home using accelerometers or other devices 49 . The use of accelerometry was pilot tested in patients with IIM 50 . A full validation study of 50 consecutive patients with IIM is ongoing at two independent centres (R.A. and O. Benveniste, unpub lished observations). Numerous variables, such as aver age daily step count and acceleration vector magnitude, can be used to describe the intensity, duration and types of activity. Although physical activity monitoring has good face validity, further studies are needed to estab lish its reliability and validity in patients with IIM. The major advantages of physical activity monitoring include practicality, objectivity, continuous longitudinal moni toring and a lack of cognitive input from the patient or the examiner. However, interpretation of the results is required, keeping in mind that the completion of phys ical activities depends mostly on behavioural factors and not only on motor capacities. Interestingly, a study showed poor agreement between actigraphy measure ments and selfreported physical activity in patients with juvenile dermatomyositis 33 . Furthermore, patients must also be able to use the monitoring devices correctly.
It is important that all tools that are specifically devel oped for adult patients are also validated in paediatric patients to take into account the motor and developmen tal issues that are specific to growing children. Children younger than 5 years of age often cannot cooperate in strength and observational functional assessment, and different equipment sizes might be required for children of different ages.
Patient-reported outcomes
The value of incorporating the patient's perspective on outcomes when conducting clinical research is increas ingly appreciated. Therapeutic trials and observational studies should include PROMs, which are the outcomes that matter most to patients. However, many clinical assessment tools that are used for rheumatic diseases were developed with limited or no patient involvement, and patients have mostly not evaluated existing PROMs for their relevance, feasibility and validity. Furthermore, not all PROMs can be used for all patients with the same disease, given the heterogeneity in disease presentation and the variable effects of disease on patients. Therefore, diseasespecific PROMs are vital to standardize clinical trial outcomes.
The available measurement tools for assessing PROMs in patients with IIM, including questionnaires that evaluate functional status, pain, fatigue and HRQoL, are summarized in Supplementary Table S1 . The HAQ (and the Childhood HAQ (CHAQ), which is completed by parents on behalf of paediatric patients) is an example of a questionnairebased assessment of daily life activi ties that was not specifically developed for patients with IIM. The HAQ and the CHAQ are PROMs that have eight functional domains, including dressing, rising, eating, walking, hygiene, reach, grip and social activi ties, and have a total of 20 functional task items. Patients selfreport their functional level on the basis of their level of difficulty in performing the task. The HAQ and the CHAQ have been well validated in adult and juvenile patients with dermatomyositis and adult patients with polymyositis; they have been translated into multiple languages; and they are one of the CSMs used in clinical trials of patients with polymyositis, dermatomyositis or juvenile dermatomyositis 3, 4, 6, 7, 51 . HRQoL is a multidimensional concept that includes physical, mental, emotional and social functioning domains and is focused on how health status affects qual ity of life. HRQoL is particularly relevant in patients with IIMs because, despite their improved prognosis with current treatment approaches, IIMs still have consider able effects on the HRQoL of patients 52, 53 . PROMs have added valuable data on both treatment efficacy and quality of life, which are immediately relevant to the management of disease activity 54 . A systematic review of published studies on HRQoL in patients with IIM and a large North American registry study of adult patients with IIM demonstrated that overall HRQoL is lower in patients with any form of IIM (that is, dermatomyositis, polymyositis or IBM) than in either healthy populations or patients with rheumatoid arthritis; furthermore, active disease, higher damage scores and chronic illness are associated with a lower quality of life 52, 55 . Patients with juvenile dermatomyositis have a substantially impaired HRQoL compared with their healthy peers, particularly in the physical domain, with physical wellbeing primarily affected by the level of functional impairment 53 . To assess HRQoL, the IMACS recommends the use of the Short Form36 (SF36) for adult patients with IIM and the Child Health Questionnaire-Parent Form 50 (CHQ-PF50) for patients with juvenile dermato myositis, although the CHQ-PF50 is costly and the SF36 has not been fully validated in patients with IIM 1, 53, 56 . The CHQ-PF50 physical summary score is one of the validated PRINTO CSMs for juvenile dermatomyositis that has good responsiveness in clinical trials 4, 7 . [60] [61] [62] . The Myositis SIG has evaluated PROMs in studies and clinical trials of patients with IIM or neuromuscular disorders accord ing to the OMERACT filters of truth, discrimination and feasibility 60 (Supplementary Table S1 ). A review of the Myositis Activities Profile for dermatomyosi tis and poly myositis, one of the few IIMspecific, vali dated PROMs that was developed with the involvement of adult patients, indicated that, although the content was deemed relevant and important to patients, there were several limitations, including the perception that many questions were vague or ambiguous and that the dimensions of 'difficulty' and 'importance' were difficult to understand 61 .
To assess the impact of IIM on the daily lives of patients, the OMERACT Myositis SIG conducted semistructured focus group interviews of patients with dermatomyositis and patients with polymyositis from three countries. Five themes emerged as essen tial elements to capture in a future IIMspecific PROM -symptoms, activity and/or participation, strategies, knowledge of disease and selfmanagement and emo tional factors 61 . From these focus group meetings, the top five rated domains included muscle symptoms, fatigue, interaction with healthcare providers and authorities, medication adverse effects and pain.
Until the work of OMERACT concludes, the recom mendations from the European Neuromuscular Centre (ENMC) workshop on IIM outcome measures could be utilized 12 , with consideration to include the SF36 and/or Myositis Activities Profile as a PROM for adult patients with dermatomyositis or polymyositis, and the CHQ-PF50, which has been validated by PRINTO, for patients with juvenile dermatomyositis 53 . For IBM, the diseasespecific Sporadic IBM Physical Functioning Assessment 63, 64 , which was developed with patient input, and the IBM functional rating scale (IBMFRS) 35, 65 , which was derived from the amyotrophic lateral sclerosis functional rating scale, are being used as end points in therapeutic trials 66 . Further work is needed to develop PROMs for IBM.
Other measures
Although individual CSMs and combinations of CSMs have been well validated as composite response crite ria for clinical trials and studies in adult and juvenile patients with dermatomyositis and adult patients with polymyositis and are most frequently used as outcome measures in therapeutic trials, the CSMs do not ade quately assess specific aspects of disease that might be important in subgroups of patients. Additional clinical measures to assess skin disease activity and damage for adult and juvenile patients with dermatomyositis and to assess pulmonary disease for patients with interstitial lung disease (ILD) have been developed and partially validated for adult and juvenile dermatomyositis and polymyositis 3, 12 . Consensus has been obtained by the ENMC outcome assessment working group to include the Cutaneous Dermatomyositis Disease Area and Severity Index to assess skin activity and damage across multiple body regions in patients with dermatomyositis. In patients with dermatomyositisassociated ILD and patients with polymyositisassociated ILD, consensus was reached to include the Myositis Disease Activity Assessment Tool, as well as the OMERACT consensus measures for connective tissueassociated ILD, including pulmonary function testing (forced vital capacity and diffusion capacity of the lung for carbon mono xide), supplemental oxygen requirement, dyspnoea scale ratings and 6MWDT 12 69 means that inactive disease has become a realistic therapeutic target for patients with juvenile dermatomyositis 70, 71 . Using a datadriven approach in a large prospective cohort of patients with juvenile dermatomyositis, the PRINTO group developed criteria for clinically inactive disease (a point in time with clinically and biologically quiescent disease, either on or off therapy), which include three of the four CSMs returning to normal or nearnormal values, including creatine kinase, CMAS, MMT and PGA
(TABLE 5).
Because residual rashes and nailfold capillary changes frequently remain after the muscle criteria of clinically inactive disease are met, requiring the PGA to return to normal improves the positive predictive value of the criteria for inactive disease 73 . Of note, criteria for inac tive disease are not yet available for adult patients with dermatomyositis, polymyositis or IBM.
The IMACS used consensus methodology to define criteria for complete clinical response for dermatomyosi tis, polymyositis, juvenile dermatomyositis and IBMthat is, a ≥6month continuous period with no evidence of disease activity while still receiving IIM therapy, as compared with substantial disease activity in the past, whereas clinical remission is defined as a ≥6month con tinuous period of inactive disease while not receiving any IIM therapy 74 . These criteria are preliminary and were proposed for juvenile dermatomyositis and adult dermatomyositis, polymyositis and IBM and have yet to be validated. The time to achieve clinical remission has been reported as a secondary end point in a therapeutic trial of children with juvenile dermato myositis but has not been validated as an end point 7 .
The IMACS has also defined, via consensus, pre liminary criteria for flare or worsening of disease, and the PRINTO has defined flare criteria for children with juvenile dermatomyositis for use as an end point in the newonset juvenile dermatomyositis trial 7, 74 (TABLE 5) . Not only can these criteria be used as an outcome in therapeu tic trials but they can also be used to determine whether a patient is not responding to an experimental therapy and should be withdrawn from a trial. The PRINTO trial used the time to prednisone discontinuation as an additional secondary longterm outcome to take into account the fact that corticosteroids are still the mainstay treatment for juvenile dermatomyositis despite the known adverse effects of corticosteroids on growth and development 7 .
Imaging
Imaging modalities might be useful in IIM outcome assessment as measures ancillary to the validated CSMs and response criteria, by providing measures that are 
Magnetic resonance imaging
(MRI). An imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.
potentially more objective than CSMs or response cri teria, and by discriminating active disease from muscle damage. Magnetic resonance imaging (MRI) is the pre ferred muscle imaging modality and can be used as a noninvasive tool to sensitively monitor disease activity and muscle damage in many muscle groups simulta neously without exposing the patient to ionizing radi ation 75, 76 . The ability to differentiate between acute and chronic muscle pathology makes MRI particularly useful. However, there is still no standardized and uni versally accepted MRI protocol or quantitative or qual itative scoring of MRI assessment in IIMs. In routine care, T2weighted sequences with fat suppression, such as the short tau inversion recovery (STIR) sequence, are used to detect water deposition or muscle oedema as part of muscle inflammation, regeneration and necro sis, whereas T1weighted sequences are usually used to detect muscle atrophy and intramuscular fat accumu lation or fibrosis as part of chronic changes 77 . MRI has also been used to clarify whether a patient is flaring and requires additional treatment or whether the muscle inflammation has resolved and therefore a reduction in therapy is supported 78 . Semiquantitative and quantitative assessments of muscle oedema and damage by MRI have poten tial as outcome measures in patients with IIM. Semi quantitative MRI scoring systems use ordinal scales of varying range to assess fatty infiltration of muscle and muscle oedema, and less frequently muscle atrophy, as well as perifascicular, subcutaneous, softtissue and fascial oedema, but these scoring systems have not been standardized 79 . In studies using semiquantitative scoring systems, total oedema and damage scores in the muscle and fascia correlated with MMT and func tional testing measures in patients with antisynthetase syndrome 80 , whereas muscle oedema correlated with PGA, muscle strength by MMT and creatine kinase lev els in patients with polymyositis or dermatomyositis 81 , and fatty infiltration of muscle correlated with muscle strength and function in patients with IBM 82 . Semi quantitative and quantitative MRI scoring methods that are used to evaluate muscle involvement in patients with IIM have been reviewed elsewhere 79 . Quantitative MRI scoring systems use continuous scales of MRI parameters that reflect muscle compo sition and/or haemodynamic properties. The most frequently used quantitative muscle imaging methods are fat fraction (which quantifies tissue fat content on a 0-100% fatfraction scale), transverse relaxation time (T2) and magnetization transfer ratio. T2 and magnetization transfer ratio are sensitive to changes in the water distribution and lipid content in muscle. In a prospective quantitative MRI study in patients with IBM, the fat fraction of whole calf muscles and thigh muscles (measured using MRI Dixon fat water imaging) increased significantly after 1 year and corre lated with the lower limb components of the IBMFRS 83 (FIG. 1) . This study demonstrated the validity and responsiveness of MRI outcome measures, particularly fat fraction, in patients with IBM, suggesting that MRI biomarkers will be valuable in therapeutic trials and have the potential to decrease sample size if used as the primary end point in earlyphase clinical trials 83 . Another study of MRI quantification in adult and juve nile patients with dermatomyositis and adult patients with polymyositis showed good construct validity of semiquantitative STIR and T1 scores, as well as quan titative maps of T2, fatcorrected T2 and fat fraction of thigh muscles, with measures of clinical disease activ ity and damage. The MRI scores were responsive to change in a subgroup of patients from the Rituximab in Myositis trial, but changes in these MRI measures did not agree well with the clinical response criteria, perhaps because only changes in muscle oedema are quantified by MRI 84 . Wholebody MRI is used at some centres and can provide a comprehensive picture of the distribution pat terns of affected muscles and reveal clinically unsus pected involvement of distal or axial muscle groups, thereby offering advantages over regional imaging 85 . Wholebody MRI can also detect associated cardio pulmonary disease, avascular necrosis and malig nancies 86 , although it is still not widely available and is prone to fatsuppression artefacts. Other emerging, but still exploratory, imaging modalities include func tional MRI, magnetic resonance spectroscopy and magnetic resonance or ultrasound elastography, which are being evaluated in patients with some subtypes of IIM 75, 76 . Realtime MRI has shown potential for eval uating dysphagia in patients with IBM 68 . Finally, total lean body mass and appendicular lean body mass meas ured by dualenergy Xray absorptiometry have been used as outcome measures in clinical trials of patients with IBM 47, 66 .
Biomarkers
Traditional biomarkers of disease activity in patients with IIMs include serum levels of creatine kinase and other musclerelated enzymes, which are part of the IMACS and PRINTO CSMs. However, the relationship Nature Reviews | Rheumatology of serum muscle enzyme activity to disease activity is variable, especially in adult and juvenile patients with dermatomyositis and patients with IBM, and therefore, a great need exists for the development of more specific and sensitive biomarkers. At present, it is established that innate and adaptive immunity, as well as non immune musclerelated mechanisms, are involved in the pathogenesis of IIMs 87, 88 . Genes and proteins related to immune activation are some of the many poten tial new biomarkers for IIMs. However, many stud ies often examine only a single biomarker of disease, and most biomarkers have not been validated in lon gitudinal or multisite studies and thus require confir mation. Immune activation results in the secretion of cytokines, chemokines and other proteins into the serum or plasma when there is active disease (TABLE 6) . The potential of these immune molecules as biomark ers was first proposed when gene expression and pro tein assays were developed and they demonstrated how complex and entwined the immune system is with IIMs.
Cytokine levels and expression, particularly IL6, are dysregulated in IIMs. Studies showed that IL6 is expressed by both immune cells and muscle cells in muscle tissue [88] [89] [90] [91] [92] . Serum IL6 levels are significantly elevated in adult and juvenile patients with dermato myositis and correlate with disease activity at diagnosis, ongoing disease changes after varying treatments and the presence of ILD.
T cellderived biomarkers include those produced by T helper 17 (T H 17) cells, such as IL17 and IL23, which are detected in the muscle and serum of patients with dermatomyositis or juvenile dermatomyositis early in the disease course and correlate with active disease [88] [89] [90] [91] 93 (TABLE 6). The levels of some biomarkers are elevated in subgroups of patients, such as the cytokine B cell activating factor (BAFF; also known as TNFSF13B), which is dysregulated at both the protein level (in serum) and the gene expression level in patients with dermatomyositis, poly myositis or juvenile dermato myositis, especially those patients with ILD, anti histidyltRNA synthetase (Jo1) autoantibodies or active disease 91, 94, 95 . In both adult and juvenile dermatomyositis, type I interferonrelated cytokines and chemokines are upreg ulated in the muscle and blood of patients who have active disease [88] [89] [90] [91] [92] [96] [97] [98] [99] [100] . In the IIMs, type I interferon regulated proteins are some of the most studied bio markers that are related to disease activity and outcome. In particular, CXCchemokine ligand 10 (CXCL10), CXCL11, CCchemokine ligand 2 (CCL2) and IL6 are highly expressed in muscle, the skin and periph eral blood, and CXCL10 is highly expressed in blood vessel endothelial cells. Furthermore, the levels of these immune molecules correlate with measures of IIM disease activity, including cutaneous disease [101] [102] [103] [104] . Other proposed biomarkers, such as myeloid cell derived molecules, adipokines and innate immune receptors, are elevated in children and adults with active dermatomyositis 90, 96, [105] [106] [107] [108] [109] [110] [111] . The level of the macro phage and endothelial cell cytokine IL8 correlates with changes in global activity scores in adult patients with ILD (including those with anti melanoma differen tiationassociated protein 5 (MDA5) auto antibody associated ILD) 90, 92, 96, 106 . A novel disease marker that was described in patients with juvenile dermato myositis, galectin 9, correlates strongly with other biomarkers, such as TNF receptor 2 (TNFR2; also known as TNFRSF1B) and CXCL10, as well as with measures of disease activity and the need for ongoing treatment 108 . Mucin 1 is expressed in the lung and is elevated in the serum of patients with dermatomyositis related ILD 110 . Serum ferritin is also elevated in patients with dermato myositis or polymyositis and ILD and is a predictor of survival 112 . A subgroup of IIM, immune mediated necrotizing myopathy, has a strong T H 1 cell response in the muscle tissue, which might inform the identification of future biomarkers and aid in diagnostic decisions 113 . Myositisspecific autoantibodies (MSAs) are increas ingly recognized in patients with any form of IIM. The detection of specific autoantibodies might identify the subtype of IIM and suggests the development of distinct clinical features and outcomes 114, 115, 116 (see the Review on myositis autoantibodies in this Focus Issue 117 ) (TABLE 6) . MSA titres have been shown to be associated with dis ease activity, and in many cases, the serum levels of MSAs decrease after therapy 116, 118, 119 . Similarly, decreases in antiMDA5 autoantibody levels have been associated with longer remission, whereas increased levels have been associated with relapses 120, 121 . Elevated MSA titres have also been associated with poorer outcomes, such as the association of high titres of antiMDA5 autoantibodies with rapidly progressive ILD 122 . Many of these biomarkers have been studied in clinical trials, including in the Rituximab in Myositis trial 6 . In this trial, correlations were found between improvement in the interferon chemokine score and improvement in global and specific measures of dis ease activity, as well in the levels of some MSAs 90, 99 . MSA titres also declined after rituximab therapy and correlated with changes in disease activity measures 116 . In particular, the serum levels of autoantibodies to Jo1, transcription intermediary factor 1γ (TIF1γ) and Mi2 decreased after rituximab treatment and showed mod erate to strong correlation with most disease activity measures. A reduction in the interferon gene score in the blood and muscle correlated with clinical improvement in muscle strength in a trial of a monoclonal antiIFNα antibody, as well as in the rituximab trial 123, 124 . Serial muscle biopsies have sometimes been used to assess treatment effects in patients with IIMs, particu larly to examine specific biomarkers 9, 10, 123, 124 . A score tool for assessing the histological severity of inflamma tion, vasculopathy and myopathic and connective tissue fibrotic changes in affected muscle has been validated in patients with juvenile dermatomyositis but not in patients with other IIMs 125 . However, the utility of out come assessment using histological biomarkers is lim ited by the invasiveness of the biopsy procedure and the lack of validation of the score tool in patients with IIMs aside from juvenile dermatomyositis. Scale for level of evidence supporting biomarker: +, 1-2 references; ++, 2-5 references; +++, >5 references; -, little or no evidence; NI, no information available. BAFF, B cell-activating factor; BCL-6, B cell lymphoma 6 protein; CCL, CC-chemokine ligand; CXCL, CXC-chemokine ligand; DM, dermatomyositis; ELISA, enzyme-linked immunosorbent assay; GATA3, GATA-binding protein 3; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase; ILD, interstitial lung disease; Jo1, histidyl-tRNA synthetase; MDA5, melanoma differentiation-associated protein 5; MRP, migration inhibitory factor-related protein; MX1, interferon-induced GTP-binding protein MX1; NXP2, nuclear matrix protein 2; PL12, alanyl-tRNA synthetase; PM, polymyositis; PM-Scl, polymyositis-scleroderma autoantigen; RORC, RAR-related orphan receptor C; SAE, small ubiquitin-like modifier activating enzyme small ubiquitin-like modifier activating enzyme; SRP, signal recognition particle; sST2, soluble suppression of tumorigenicity protein T2; STAT, signal transducer and activator of transcription; T H , T helper; TIF1, transcriptional intermediary factor 1.
a Changes with disease activity.
Conclusions
The development and dissemination of many validated outcome assessment measures for IIM disease activity and damage have brought standardization to the field, which has aided in our understanding of the longterm outcomes of these diseases and in developing and eval uating new therapies. The new IIM response criteria for dermatomyositis, polymyositis and juvenile dermato myositis should provide a more robust and sensitive composite end point to detect clinical responses of different magnitudes. Additional measures of muscle strength and function, as well as the assessment of other target organs and HRQoL, require further development and validation but show promise in advancing new tools with good content and construct validity. These meas ures might also be used as end points in trials, including potentially as part of future composite response criteria, in studies of specific organ manifestations (such as for skin or pulmonary disease) or for a specific subgroup of patients. Imaging and biomarkers are objective measures that can discriminate disease activity from damage, but they require standardization and further evaluation of their capacity to discern the effects of therapies and their sensitivity to change. We regard the use of the CSMs and the response criteria as central to outcome assessment in all IIM therapeutic trials, which will facilitate interna tional use, standardization of end points and compar isons between studies, therapies and patient subgroups and might be applied in the clinic to guide therapeutic decisions. Further development of additional outcome measures might result in a targeted assessment of spe cific disease features to augment the CSMs. We envision future development of additional measures and indi ces that are more sensitive and objective than current measures. Furthermore, obtaining realtime, reallife data from patients through the use of smartphone applications and actigraphy might augment our current targeted clinical assessments. Finally, although the vari ous outcome measures are often presented as competing, they should be considered as complementary.
